Patents written and products formulated by
Dr. Timothy M. Marshall, Ph.D.
FoodPharma’s Chief Science Officer
Neuropharmacologist, Nutritional Biochemist
WHAT’S BETTER THAN A PILL?
A HIGHLY-BIOAVAILABLE FOOD-FORM DELIVERY SYSTEM
This revolutionary, patent-pending formula is provided in an equally unique patent-pending small molecule delivery system, which surpasses traditional tablets, capsules, powders, and gummies with immediate uptake into the systemic circulation via oral microvascular absorption for exceptional bioavailability and maximum consumer benefit.
The rich-blood supply of the oral mucosa and “sticky”, mucoadhesive properties of this novel, nutrient-dense, saccharide-based delivery system allows for the efficient absorption of small molecules (< 500 Da) via paracellular and transcellular transport across several highly-vascularized surfaces including the gingival and buccal mucosa.
SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM
FOR NEUROTROPHIC AND NEUROPROTECTIVE COMPOSITIONS
CROSS REFERENCE TO RELATED APPLICATION
 This application claims priority from United States Provisional Patent Application No.62/696,995, filed July 12, 2018 and entitled “A NOVEL, SACCHARIDE-BASED, ORAL MUCOADHESIVE DELIVERY SYSTEM FOR FAST-ACTING, NEUROTROPHIC AND NEUROPROTECTIVE BENEFITS,” the disclosures of which are hereby incorporated entirely herein by reference.
BACKGROUND OF THE INVENTION
 This invention generally relates to delivery systems, and more particularly to a saccharide- based oral mucoadhesive delivery system for administration of neurotrophic and neuroprotective compositions.
ABSTRACT OF THE DISCLOSURE
 The oral cavity is an ideal-site for small molecule, nutrient/nutraceutical delivery to the central nervous system (CNS) and systemic circulation due to the highly-vascularized, oral mucosa, near-neutral pH conditions, close proximity to the brain, and avoidance of gastric degradation and the first-pass effect. The rich-blood supply of the oral mucosa and “sticky”, mucoadhesive properties of this novel, saccharide-based, delivery system allows for the efficient absorption of small molecules across several highly-vascularized surfaces including the gingival, sublingual, soft-palatal, and buccal mucosa. Herein, I introduce a novel, saccharide-based, food-form, palatable, easy-to-administer, oral delivery system that attaches to these four, highly-absorptive surfaces for a longer contact-duration than current orally-available formulas resulting in greater, small molecule bioavailability, and a more rapid, therapeutic effect. This invention represents the next-generation in optimized, highly- efficacious, small molecule delivery systems for CNS-related conditions that moves one-step closer in approximating intravenous injection in systemic bioavailability and therapeutic onset.